<DOC>
	<DOCNO>NCT00025129</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness VNP40101M treat patient advance solid tumor lymphomas .</brief_summary>
	<brief_title>VNP40101M Treating Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose VNP40101M patient advance solid tumor lymphomas . - Determine toxic effect drug patient . - Determine pharmacokinetics drug patient . - Determine anti-tumor effect drug patient . OUTLINE : This dose-escalation study . Patients receive VNP40101M IV 15 minute day 1 . Treatment repeat every 4 week 8 course absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos VNP40101M maximum tolerate dose ( MTD ) determine . The MTD define high dose 1 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 20-30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced and/or metastatic solid tumor lymphoma curative standard effective therapy exist Measurable evaluable metastatic disease No hematologic malignancy No large pleural , pericardial , peritoneal effusion No requirement immediate palliative treatment , include surgery No symptomatic brain metastasis metastases substantial edema Asymptomatic brain metastasis primary CNS disease allow neurologic deficit stable PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 3 month Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hematocrit least 30 % ( transfusion allow ) No active uncontrolled bleeding Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT AST great 1.5 time ULN ( 3 time ULN liver metastasis present ) Alkaline phosphatase great 1.5 time ULN ( 3 time ULN liver bone metastasis present ) PT aPTT great 1.5 time ULN Albumin least 2.5 g/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : Ejection fraction least 45 % No active heart disease No myocardial infarction within past 3 month No symptomatic coronary artery disease No arrhythmia require medication No uncontrolled congestive heart failure Pulmonary : DLCO FEV_1 least 60 % predict No dyspnea minimal moderate exertion Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation HIV negative No active infection Persistent stable chronic toxic effect prior therapy allow great grade 1 No bleeding diathesis ( e.g. , active peptic ulcer disease ) PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic agent recover At least 6 month since prior highdose chemotherapy regimen stem cell support Chemotherapy : See Biologic therapy At least 3 week since prior cytotoxic agent ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : At least 2 week since prior hormonal therapy recover Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : See Disease Characteristics At least 2 week since prior surgery recover Other : No concurrent standard therapy cancer No concurrent investigational agent No concurrent disulfiram ( Antabuse )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2004</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>